We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
Read MoreHide Full Article
Biogen (BIIB - Free Report) announced that the European Medicines Agency (EMA) has accepted the marketing authorization application seeking approval of antisense drug, tofersen in patients with amyotrophic lateral sclerosis (“ALS”) with superoxide dismutase 1 (“SOD1”) mutation.
ALS is a rare neurodegenerative disease whose progression leads to a steady decline in the ability to move, speak, eat and eventually breathe. The average life expectancy of people with this often-fatal disease ranges from three to five years. SOD1-mutated ALS is a genetic form of ALS that currently accounts for 2% of the ALS population. There is currently no treatment available for SOD1-ALS. If approved, tofersen will be the first genetically-targeted treatment for SOD1-ALS in Europe. SOD1-ALS affects less than 1,000 people in Europe
Biogen’s new drug application (NDA) for tofersen is under review with the FDA. In October, the FDA extended the review period for the NDA. Following the extension of the NDA review, a final decision from the FDA is expected by Apr 25, 2023. Prior to the extension, the FDA had originally set a target action date of January 2023.
Biogen’s regulatory filings for tofersen were supported by data from the phase III VALOR study, its open-label extension (OLE) study and a couple of early-stage studies.
Biogen’s stock has risen 22% this year so far against a decline of 16.3% for the industry.
Image Source: Zacks Investment Research
Though the VALOR study did not achieve statistical significance in primary endpoints, data from the same demonstrated that patients who started tofersen earlier reported signs of reduced disease progression across multiple measures. The signs included a reduction in SOD1 protein, a drop in neurofilament and an improvement in respiratory function compared with a placebo.
Data from the VALOR study also showed that compared with the delayed initiation of treatment, the earlier initiation of treatment with tofersen showed clinical benefit in study participants. An earlier start of treatment with tofersen led to a slowed decline in clinical function, respiratory function, muscle strength and quality of life.
Biogen in-licensed rights to tofersen from Ionis Pharmaceuticals (IONS - Free Report) under a collaborative development and license agreement entered in 2018. Apart from tofersen, Biogen is also collaborating with Ionis to develop ION541 for ALS (phase II) and ION859 for Parkinson’s disease (phase I/II).
Biogen and Ionis already have an existing marketed drug, Spinraza, which has now become the standard-of-care treatment for treating spinal muscular atrophy (SMA). While Biogen is responsible for Spinraza’s sales, Ionis receives royalties on the same.
Vertex Pharmaceuticals’ stock has risen 44.6% this year so far. Estimates for Vertex’s 2022 earnings have gone up from $14.21 to $14.61 per share, while that for 2023 have increased from $15.09 to $15.60 per share over the past 60 days. Vertex has a four-quarter earnings surprise of 3.16%, on average.
Estimates for Gilead’s 2022 earnings per share have increased from $6.61 per share to $7.09 per share, while that for 2023 have increased from $6.30 per share to $6.80 per share in the past 30 days. Gilead’s stock is up 21.1% in the year-to-date period.
Gilead beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 0.36%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
Biogen (BIIB - Free Report) announced that the European Medicines Agency (EMA) has accepted the marketing authorization application seeking approval of antisense drug, tofersen in patients with amyotrophic lateral sclerosis (“ALS”) with superoxide dismutase 1 (“SOD1”) mutation.
ALS is a rare neurodegenerative disease whose progression leads to a steady decline in the ability to move, speak, eat and eventually breathe. The average life expectancy of people with this often-fatal disease ranges from three to five years. SOD1-mutated ALS is a genetic form of ALS that currently accounts for 2% of the ALS population. There is currently no treatment available for SOD1-ALS. If approved, tofersen will be the first genetically-targeted treatment for SOD1-ALS in Europe. SOD1-ALS affects less than 1,000 people in Europe
Biogen’s new drug application (NDA) for tofersen is under review with the FDA. In October, the FDA extended the review period for the NDA. Following the extension of the NDA review, a final decision from the FDA is expected by Apr 25, 2023. Prior to the extension, the FDA had originally set a target action date of January 2023.
Biogen’s regulatory filings for tofersen were supported by data from the phase III VALOR study, its open-label extension (OLE) study and a couple of early-stage studies.
Biogen’s stock has risen 22% this year so far against a decline of 16.3% for the industry.
Image Source: Zacks Investment Research
Though the VALOR study did not achieve statistical significance in primary endpoints, data from the same demonstrated that patients who started tofersen earlier reported signs of reduced disease progression across multiple measures. The signs included a reduction in SOD1 protein, a drop in neurofilament and an improvement in respiratory function compared with a placebo.
Data from the VALOR study also showed that compared with the delayed initiation of treatment, the earlier initiation of treatment with tofersen showed clinical benefit in study participants. An earlier start of treatment with tofersen led to a slowed decline in clinical function, respiratory function, muscle strength and quality of life.
Biogen in-licensed rights to tofersen from Ionis Pharmaceuticals (IONS - Free Report) under a collaborative development and license agreement entered in 2018. Apart from tofersen, Biogen is also collaborating with Ionis to develop ION541 for ALS (phase II) and ION859 for Parkinson’s disease (phase I/II).
Biogen and Ionis already have an existing marketed drug, Spinraza, which has now become the standard-of-care treatment for treating spinal muscular atrophy (SMA). While Biogen is responsible for Spinraza’s sales, Ionis receives royalties on the same.
Zacks Rank & Stocks to Consider
Biogen has a Zacks Rank #2 (Buy) currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some other large biotech stocks worth considering are Vertex Pharmaceuticals (VRTX - Free Report) and Gilead Sciences (GILD - Free Report) , all carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex Pharmaceuticals’ stock has risen 44.6% this year so far. Estimates for Vertex’s 2022 earnings have gone up from $14.21 to $14.61 per share, while that for 2023 have increased from $15.09 to $15.60 per share over the past 60 days. Vertex has a four-quarter earnings surprise of 3.16%, on average.
Estimates for Gilead’s 2022 earnings per share have increased from $6.61 per share to $7.09 per share, while that for 2023 have increased from $6.30 per share to $6.80 per share in the past 30 days. Gilead’s stock is up 21.1% in the year-to-date period.
Gilead beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 0.36%, on average.